leadf
logo-loader
viewHikma Pharmaceuticals PLC

Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product.

As Howell explains, this deal follows on from the first agreement signed in January to develop a product using Arecor’s proprietary drug formulation technology platform Arestat.

Howell hints that there could be a potential third deal in the pipeline considering the 'strength of this collaboration'.

Quick facts: Hikma Pharmaceuticals PLC

Price: 2547 GBX

AIM:HIK
Market: AIM
Market Cap: £5.87 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ascendant Resources drill program continues looking to expand south zone at...

Ascendant Resources (TSE: AND) President and CEO Chris Buncic joined Steve Darling from Proactive with news the company's drill program continues as the look at the South Zone of the Lagoa Salgada Project in Portugal. Buncic telling Proactive they are expecting to have results from this...

8 hours, 49 minutes ago

2 min read